Compare CIF & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | CIF | COCH |
|---|---|---|
| Founded | 1988 | 1995 |
| Country | United States | United States |
| Employees | N/A | 47 |
| Industry | Trusts Except Educational Religious and Charitable | Blank Checks |
| Sector | Finance | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.8M | 49.7M |
| IPO Year | N/A | N/A |
| Metric | CIF | COCH |
|---|---|---|
| Price | $1.59 | $0.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 51.7K | ★ 123.9K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 10.11% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.58 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.57 | $0.36 |
| 52 Week High | $1.82 | $1.89 |
| Indicator | CIF | COCH |
|---|---|---|
| Relative Strength Index (RSI) | 40.57 | 40.26 |
| Support Level | $1.57 | $0.64 |
| Resistance Level | $1.73 | $0.73 |
| Average True Range (ATR) | 0.02 | 0.03 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 50.00 | 3.04 |
Mfs Intermediate High Income Fund is a United States-based diversified closed-end management investment company. Its investment objective is to seek high current income, but it may also consider capital appreciation. The fund invests a majority of its net assets, including borrowings for investment purposes, in high-income debt instruments. Its portfolio of investments includes investment-grade corporate bonds, government securities and other securities. The portfolio includes Midstream, Financial Institutions, Energy, Cable TV, and Utilities.
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.